Literature DB >> 23046130

Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA.

Jean-Philippe Julien1, Peter S Lee, Ian A Wilson.   

Abstract

Human immunodeficiency virus-1 (HIV-1) envelope protein (Env) and influenza hemagglutinin (HA) are the surface glycoproteins responsible for viral entry into host cells, the first step in the virus life cycle necessary to initiate infection. These glycoproteins exhibit a high degree of sequence variability and glycosylation, which are used as strategies to escape host immune responses. Nonetheless, antibodies with broadly neutralizing activity against these viruses have been isolated that have managed to overcome these barriers. Here, we review recent advances in the structural characterization of these antibodies with their viral antigens that defines a few sites of vulnerability on these viral spikes. These broadly neutralizing antibodies tend to focus their recognition on the sites of similar function between the two viruses: the receptor-binding site and membrane fusion machinery. However, some sites of recognition are unique to the virus neutralized, such as the dense shield of oligomannose carbohydrates on HIV-1 Env. These observations are discussed in the context of structure-based design strategies to aid in vaccine design or development of antivirals.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23046130      PMCID: PMC3479221          DOI: 10.1111/imr.12005

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  199 in total

1.  Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region.

Authors:  Gilad Ofek; Krisha McKee; Yongping Yang; Zhi-Yong Yang; Jeff Skinner; F Javier Guenaga; Richard Wyatt; Michael B Zwick; Gary J Nabel; John R Mascola; Peter D Kwong
Journal:  J Virol       Date:  2009-12-30       Impact factor: 5.103

2.  Antigenic mimicry of the HIV envelope by AIDS-associated pathogens.

Authors:  D Cameron Dunlop; Alexander Ulrich; Ben J Appelmelk; Dennis R Burton; Raymond A Dwek; Nicole Zitzmann; Christopher N Scanlan
Journal:  AIDS       Date:  2008-10-18       Impact factor: 4.177

3.  Interim within-season estimate of the effectiveness of trivalent inactivated influenza vaccine--Marshfield, Wisconsin, 2007-08 influenza season.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2008-04-18       Impact factor: 17.586

4.  Glycan shielding of the influenza virus hemagglutinin contributes to immunopathology in mice.

Authors:  Keith Wanzeck; Kelli L Boyd; Jonathan A McCullers
Journal:  Am J Respir Crit Care Med       Date:  2010-10-08       Impact factor: 21.405

5.  Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies.

Authors:  Sang-Moo Kang; Fu Shi Quan; Chunzi Huang; Lizheng Guo; Ling Ye; Chinglai Yang; Richard W Compans
Journal:  Virology       Date:  2005-01-05       Impact factor: 3.616

6.  Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1.

Authors:  Aran F Labrijn; Pascal Poignard; Aarti Raja; Michael B Zwick; Karla Delgado; Michael Franti; James Binley; Veronique Vivona; Christoph Grundner; Chih-Chin Huang; Miro Venturi; Christos J Petropoulos; Terri Wrin; Dimiter S Dimitrov; James Robinson; Peter D Kwong; Richard T Wyatt; Joseph Sodroski; Dennis R Burton
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Interactions between lipids and human anti-HIV antibody 4E10 can be reduced without ablating neutralizing activity.

Authors:  Hengyu Xu; Likai Song; Mikyung Kim; Margaret A Holmes; Zane Kraft; George Sellhorn; Ellis L Reinherz; Leonidas Stamatatos; Roland K Strong
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

8.  The contents of the syringe.

Authors:  Steven Salzberg
Journal:  Nature       Date:  2008-07-10       Impact factor: 49.962

9.  Increasing the potency and breadth of an HIV antibody by using structure-based rational design.

Authors:  Ron Diskin; Johannes F Scheid; Paola M Marcovecchio; Anthony P West; Florian Klein; Han Gao; Priyanthi N P Gnanapragasam; Alexander Abadir; Michael S Seaman; Michel C Nussenzweig; Pamela J Bjorkman
Journal:  Science       Date:  2011-10-27       Impact factor: 47.728

10.  Why is HIV a pathogen?

Authors:  Anna Forsman; Robin A Weiss
Journal:  Trends Microbiol       Date:  2008-10-30       Impact factor: 17.079

View more
  61 in total

Review 1.  HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth.

Authors:  Priyamvada Acharya; Sabrina Lusvarghi; Carole A Bewley; Peter D Kwong
Journal:  Expert Opin Ther Targets       Date:  2015-02-27       Impact factor: 6.902

2.  Antibody recognition of the pandemic H1N1 Influenza virus hemagglutinin receptor binding site.

Authors:  Minsun Hong; Peter S Lee; Ryan M B Hoffman; Xueyong Zhu; Jens C Krause; Nick S Laursen; Sung-Il Yoon; Langzhou Song; Lynda Tussey; James E Crowe; Andrew B Ward; Ian A Wilson
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

3.  Immunodominance and Antigenic Variation of Influenza Virus Hemagglutinin: Implications for Design of Universal Vaccine Immunogens.

Authors:  Seth J Zost; Nicholas C Wu; Scott E Hensley; Ian A Wilson
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

Review 4.  VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design.

Authors:  Fang Chen; Netanel Tzarum; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2019-03-16       Impact factor: 7.090

5.  HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies.

Authors:  Rebecca M Lynch; Patrick Wong; Lillian Tran; Sijy O'Dell; Martha C Nason; Yuxing Li; Xueling Wu; John R Mascola
Journal:  J Virol       Date:  2015-01-28       Impact factor: 5.103

Review 6.  Advances in structure-based vaccine design.

Authors:  Daniel W Kulp; William R Schief
Journal:  Curr Opin Virol       Date:  2013-06-25       Impact factor: 7.090

7.  Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains.

Authors:  Daniela Fera; Aaron G Schmidt; Barton F Haynes; Feng Gao; Hua-Xin Liao; Thomas B Kepler; Stephen C Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-30       Impact factor: 11.205

8.  Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9.

Authors:  Jean-Philippe Julien; Jeong Hyun Lee; Albert Cupo; Charles D Murin; Ronald Derking; Simon Hoffenberg; Michael J Caulfield; C Richter King; Andre J Marozsan; Per Johan Klasse; Rogier W Sanders; John P Moore; Ian A Wilson; Andrew B Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-20       Impact factor: 11.205

9.  Rational HIV immunogen design to target specific germline B cell receptors.

Authors:  Joseph Jardine; Jean-Philippe Julien; Sergey Menis; Takayuki Ota; Oleksandr Kalyuzhniy; Andrew McGuire; Devin Sok; Po-Ssu Huang; Skye MacPherson; Meaghan Jones; Travis Nieusma; John Mathison; David Baker; Andrew B Ward; Dennis R Burton; Leonidas Stamatatos; David Nemazee; Ian A Wilson; William R Schief
Journal:  Science       Date:  2013-03-28       Impact factor: 47.728

10.  Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine.

Authors:  Sita Awasthi; Robert B Belshe; Harvey M Friedman
Journal:  J Infect Dis       Date:  2014-03-20       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.